Pluristem Therapeutics, Inc. (NASDAQ:PSTI)‘s stock had its “buy” rating reissued by analysts at Seaport Global Securities in a report issued on Friday, Marketbeat reports. They currently have a $5.00 price objective on the biotechnology company’s stock. Seaport Global Securities’ target price points to a potential upside of 233.33% from the stock’s previous close. Seaport Global Securities also issued estimates for Pluristem Therapeutics’ Q3 2018 earnings at ($0.09) EPS.

A number of other analysts have also recently issued reports on PSTI. Maxim Group raised shares of Pluristem Therapeutics from a “hold” rating to a “buy” rating and set a $2.00 price objective for the company in a research note on Monday, June 19th. HC Wainwright set a $4.00 price objective on shares of Pluristem Therapeutics and gave the stock a “buy” rating in a research note on Thursday, August 17th. ValuEngine cut shares of Pluristem Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Friday, September 1st. Finally, Zacks Investment Research cut shares of Pluristem Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, September 22nd. Two equities research analysts have rated the stock with a sell rating and four have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $4.13.

Pluristem Therapeutics (NASDAQ:PSTI) opened at 1.49 on Friday. The company has a 50-day moving average of $1.34 and a 200-day moving average of $1.31. Pluristem Therapeutics has a 1-year low of $1.04 and a 1-year high of $1.65. The stock’s market capitalization is $145.23 million.

COPYRIGHT VIOLATION NOTICE: This piece was originally posted by Watch List News and is the property of of Watch List News. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The correct version of this piece can be read at

A hedge fund recently raised its stake in Pluristem Therapeutics stock. Jane Street Group LLC lifted its position in Pluristem Therapeutics, Inc. (NASDAQ:PSTI) by 62.4% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 108,830 shares of the biotechnology company’s stock after purchasing an additional 41,796 shares during the period. Jane Street Group LLC owned about 0.11% of Pluristem Therapeutics worth $134,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 4.47% of the company’s stock.

About Pluristem Therapeutics

Pluristem Therapeutics Inc is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Company’s lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome.

Receive News & Ratings for Pluristem Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.